Cyclacel Continues Lung-Cancer Study
Cyclacel Pharmaceuticals Inc. said Monday it will continue enrolling patients in its midstage program for lung-cancer treatment candidate seliciclib, despite a shortage of continuing patients.
This entry was posted on Monday, November 26th, 2007 at 4:18 pm and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.